Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trefentanil is a synthetic opioid analgesic belonging to the fentanyl family. It is an extremely potent μ-opioid receptor agonist, structurally related to fentanyl, carfentanil, and remifentanil. Like other members of this class, trefentanil acts primarily by binding to and activating the μ-opioid receptor in the central nervous system, leading to profound analgesia and sedation. Trefentanil was developed for use as an anesthetic adjunct due to its rapid onset and short duration of action. Its potency is similar or greater than that of fentanyl but less than carfentanil. Due to its high potency and risk profile (notably severe respiratory depression), it has not been widely adopted in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trefentanil.